UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): DECEMBER 30, 2004
--------------------
PHARMAFRONTIERS CORP.
(Exact Name of Registrant as Specified in Its Charter)
TEXAS
(State or Other Jurisdiction of Incorporation)
000-25513 76-0333165
--------- ----------
(Commission File Number) (I.R.S. Employer Identification No.)
2408 TIMBERLOCH PLACE, SUITE B-7
THE WOODLANDS, TEXAS 77380
-------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (281) 272-9331
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 1.01. AMENDMENT OF A MATERIAL AGREEMENT.
On December 30, 2004, Registrant entered into an Amended and Restated
License Agreement (the "Amended License Agreement") with the University of
Chicago amending and restating the License Agreement dated February 20, 2004
between the Registrant and the University of Chicago. The Registrant will
request confidential treatment from the Commission for certain terms in the
Amended License Agreement in connection with the filing of the Amended License
Agreement as an exhibit to its Annual Report on Form 10-K for the year ended
December 31, 2004.
On January 4, 2005 Registrant issued a press release reporting the
signing of the Amended License Agreement. A copy of the press release is
attached as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibit
The following exhibits are to be filed as part of this 8-K:
Exhibit No. Description
- ----------- -----------
99.1 Press release issued January 4, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMAFRONTIERS CORP.
By: /s/ David B. McWilliams
------------------------------------
David B. McWilliams, Chief Executive
Officer
DATE: January 4, 2005
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release issued January 4, 2005.